Isoxicam

Isoxicam is an orally active nonsteroidal anti-inflammatory compound and a COX-1/COX-2 inhibitor. Isoxicam exhibits potent anti-inflammatory activity in rat models of inflammation and significantly lower ulcerogenic risk. Isoxicam can be used for the study of inflammatory diseases and rheumatic disorders^[1][2]. In Vivo:Isoxicam (W 8495) (6.25-50 mg/kg; p.o.) exhibits dose-dependent inhibition of carrageenin-induced paw edema in intact and adrenalectomized rats, with prolonged activity detectable up to 24 hours post-administration^[2].
Isoxicam (0.391-50 mg/kg; p.o.; daily, alternate days; days 1-20, days 14-27) exhibits dose-dependent prophylactic and therapeutic anti-arthritic activity in adjuvant-induced polyarthritis in rats, with prolonged activity detectable after treatment cessation^[2].
Isoxicam (125-1000 mg/kg; p.o.) has significantly lower gastric and intestinal ulcerogenic potential than comparator anti-inflammatory drugs, with gastric ulcer incidence ED₅₀ 252 mg/kg and intestinal ulcer incidence ED₅₀ 822 mg/kg, showing no mortality at tested doses^[2].